Dr. Gregory Cote, MD
Claim this profileMassachusetts General Hospital
Studies Cancer
Studies Soft Tissue Sarcoma
19 reported clinical trials
27 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
TAZ-CAMTA1 positive
2Soft Tissue Sarcoma
Stage IV
Stage III
SMARCB1 positive
Affiliated Hospitals
Clinical Trials Gregory Cote, MD is currently running
INBRX-109
for Chondrosarcoma
This trial tests INBRX-109, a specially designed protein, in patients with a hard-to-treat type of bone cancer. The treatment helps the immune system target and kill cancer cells by attaching to a specific marker on these cells.
Recruiting0 awards Phase 26 criteria
Tazemetostat + Doxorubicin
for Sarcoma
The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue. Part 1 of this trial will evaluate the safety and the level of the study drug that the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for the next part of the study. Part 2 will evaluate and compare for each of the study drug combinations how long participants live without their disease getting worse. The study drug is called tazemetostat. The study will test tazemetostat in combination with doxorubicin compared to placebo (dummy treatment) in combination with doxorubicin. Doxorubicin is a current front line treatment for epithelioid sarcoma
Recruiting1 award Phase 312 criteria
More about Gregory Cote, MD
Clinical Trial Related6 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Gregory Cote, MD has experience with
- Lurbinectedin
- Nivolumab
- Peposertib
- Tuvusertib
- FHD-609
- Doxorubicin
Breakdown of trials Gregory Cote, MD has run
Cancer
Soft Tissue Sarcoma
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gregory Cote, MD specialize in?
Gregory Cote, MD focuses on Cancer and Soft Tissue Sarcoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Gregory Cote, MD currently recruiting for clinical trials?
Yes, Gregory Cote, MD is currently recruiting for 6 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Gregory Cote, MD has studied deeply?
Yes, Gregory Cote, MD has studied treatments such as Lurbinectedin, Nivolumab, Peposertib.
What is the best way to schedule an appointment with Gregory Cote, MD?
Apply for one of the trials that Gregory Cote, MD is conducting.
What is the office address of Gregory Cote, MD?
The office of Gregory Cote, MD is located at: Massachusetts General Hospital, Boston, Massachusetts 02114 United States. This is the address for their practice at the Massachusetts General Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.